Ambassador Ertharin Cousin, U.S. representative to the U.N. Agencies for Food and Agriculture in Rome, writes about her recent visit to the Dadaab refugee camps in Kenya in the State Department’s “DipNote” blog. “There is something remarkable about seeing how U.S. contributions â€“ both from our government and the private sector â€“ can be transformed into something as concrete and life-saving as a simple meal for a little girl. Washington has committed around $580 million to the relief effort. Hopefully that will save a lot more children here in Dadaab and around the Horn. The international community has provided around $1.4 billion, but it’s not enough â€“ I know that and we continue to push for more support from other donors. But it is a start and it is making a real and lasting difference,” she writes (8/12).
Private Sector Involvement
Sending Surplus Medical Supplies To Developing Country Hospitals 'Not The Antidote' To Poor Conditions
“Every year, hospitals in America throw away thousands of tons of usable medical supplies and equipment â€“ by some measures 7,000 tons a year, a value of $20 billion. â€¦ Yet every year, hospitals in developing countries around the world turn away patients or provide substandard care because they lack even the most basic medical equipment,” journalist and author Tina Rosenberg writes in the New York Times’ “Opinionator” blog. She describes the work of several organizations that collect excess or unwanted medical supplies and redistribute them to hospitals in need in developing countries.
U.N. Secretary-General Ban Ki-moon “triggered a political controversy last week when he implicitly declared that even human rights have a market price,” Inter Press Service reports, noting Ban “admitted it is not acceptable that poor slum-dwellers pay five or even 10 times as much for their water as wealthy residents of the same cities.”
Speaking at the Saving Lives at Birth Development Exchange at the State Department on Thursday, Secretary of State Hillary Rodham Clinton “prais[ed] innovators from around the globe for their work to protect the health and lives of mothers and children at birth, particularly in rural areas of the developing world,” IPP Digital reports (Babb, 7/28).
The Financial Times examines the rise of product development partnerships (PDPs), which are “non-governmental organizations that generate their own funding and build partnerships with universities, businesses, government and patients in low-income countries to develop new drugs, vaccines, prevention techniques and diagnostics for diseases such as tuberculosis, HIV, malaria, cholera and meningitis.”
“In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool,” the New York Times reports (McNeil, 7/12).
Health ministers from Brazil, Russia, India, China, and South Africa in Beijing “on Monday vowed to improve access to low-cost and high-quality medicine â€“ and called on developed nations to shoulder responsibility in helping the poor,” Agence France-Presse reports (7/11).
EU Countries Should Pool Funding To Create ‘Prize’ For Bringing New Antibiotics To Market, Report Says
“European policy makers were urged Wednesday to find viable financial incentives to get drug companies to discover new antibiotics, because the lack of fresh supplies poses acute dangers to health care and efforts against infectious diseases,” according to a report by the Office of Health Economics and funded by GlaxoSmithKline, Dow Jones/Wall Street Journal reports.
The NIH in a press release said it will begin work on a “new programÂ to discover, develop and distribute measures of nutritional status.” The Biomarkers of Nutrition for Development (BOND) Program “brings together experts in the field of nutrition to provide advice to researchers, clinicians, program- and policymakers, on the…
Researchers from Scynexis Inc. of Research Triangle Park, N.C., and Anacor Pharmaceuticals in Palo Alto, Calif., sponsored by the Drugs for Neglected Diseases initiative, on Tuesday reported in the journal PLoS Neglected Tropical Diseases that a new experimental drug kills the parasite that causes African sleeping sickness in mice and will enter human clinical trials this year, ScienceNOW reports (Leslie, 6/28).